CN115925854B - Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities - Google Patents

Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities Download PDF

Info

Publication number
CN115925854B
CN115925854B CN202211672882.7A CN202211672882A CN115925854B CN 115925854 B CN115925854 B CN 115925854B CN 202211672882 A CN202211672882 A CN 202211672882A CN 115925854 B CN115925854 B CN 115925854B
Authority
CN
China
Prior art keywords
peptide
millet
cholesterol esterase
pancreatic lipase
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211672882.7A
Other languages
Chinese (zh)
Other versions
CN115925854A (en
Inventor
沈群
赵卿宇
郝智慧
张馨予
赵亮星
王超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Agricultural University
Original Assignee
China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Agricultural University filed Critical China Agricultural University
Priority to CN202211672882.7A priority Critical patent/CN115925854B/en
Priority to CN202311088956.7A priority patent/CN117003845B/en
Publication of CN115925854A publication Critical patent/CN115925854A/en
Application granted granted Critical
Publication of CN115925854B publication Critical patent/CN115925854B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present application provides two millet prolamin peptides WQHQY and WQHMMP that inhibit pancreatic lipase and cholesterol esterase activities. The millet prolamin peptide has the characteristics of nature, no toxicity, no carcinogenicity, small molecular weight and no digestion by gastrointestinal tracts, has high pancreatic lipase and cholesterol esterase inhibition activity, is simple in preparation method, is easy for industrial production, and can be prepared in a large scale; can be used as a novel lipid digestive enzyme inhibitor, can be further developed and utilized as a high-quality raw material in the fields of medicines, foods, health products and the like, is beneficial to preventing, relieving and treating hyperlipidemia, and has higher economic value and good market prospect.

Description

Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities
Technical Field
The application belongs to the field of bioactive peptides and the field of metabolic diseases treatment, and particularly provides two millet prolamin peptides for inhibiting activities of pancreatic lipase and cholesterol esterase.
Background
Hyperlipidemia (also called dyslipidemia) generally refers to elevated serum triglyceride, cholesterol, low-density lipoprotein cholesterol, and reduced high-density lipoprotein cholesterol, which is a common and frequent systemic disease in clinic, and is mainly related to congenital lipid metabolism deficiency, bad life habit, environmental factors and the like. Currently, the overall prevalence of dyslipidemia in adults in China is as high as 40.4%, and increases year by year. In addition, the development trend of 'low age' of dyslipidemia also appears, and the detection rate of dyslipidemia of children and teenagers is continuously improved. Hyperlipidemia is an important risk factor for cardiovascular disease, atherosclerosis, thrombosis, stroke and liver injury, and can raise blood uric acid levels, increase the incidence of pancreatitis, and increase the risk of developing tumors. Studies indicate that sustained abnormalities in blood lipid levels in humans will lead to 920 ten thousand increases in chinese cardiovascular events during 2010-2030, suggesting that future chinese adult hyperlipidemia and related disease burden will continue to be exacerbated. Currently, conventional lipid-lowering drugs are various in variety such as statins, fibrates, nicotinic acids and the like, and statin drugs which are most commonly used have good tolerance, but may cause adverse reactions such as muscle toxicity, headache, respiratory tract infection, liver enzyme abnormality, hemorrhagic cerebral apoplexy and the like. In addition, the statin drugs have single therapeutic targets, mainly limit cholesterol synthesis rate-limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, and have insignificant effects on lipid metabolism abnormality caused by other reasons. Along with the rapid rise of the incidence of hyperlipidemia, the development of safe and effective medicines for preventing and treating the hyperlipidemia has become a research and development hot spot in the related fields at home and abroad.
Pancreatic lipase is an important digestive tract endogenous enzyme that is released into the gastrointestinal system after secretion by the mammalian pancreas, and that, in cooperation with bile acid salts secreted by the liver, degrades fat into monoglycerides and free fatty acids. Cholesterol esterase is an alpha/beta hydrolase secreted from the pancreas, mainly present in the lumen of the small intestine, and catalyzes the release of cholesterol and free fatty acids from dietary cholesterol esters. In recent years, more and more researches indicate that inhibiting pancreatic lipase and cholesterol esterase can reduce the decomposition and absorption of dietary fat in digestive organs, thereby improving metabolic diseases such as hyperlipidemia and the like. Therefore, development of novel inhibitors of lipid digestive enzymes (pancreatic lipase and cholesterol esterase) has received great attention in the field of hyperlipidemia control.
Compared with the conventional chemical medicaments, the bioactive peptide has the advantages of less adverse reaction, high safety, multi-target effect, capability of achieving the therapeutic effects of synergism and toxicity reduction and the like, and has become the key point of research on lipid digestive enzyme inhibitors. However, the bioactive peptide is usually derived from proteolytic release, and because the components contained in the protein hydrolysate are complex, the protein hydrolysate has blindness if being developed one by one, and has the problems of long research period, high capital cost and the like, so that the bioactive peptide screening based on the bioinformatics technology has important application value for developing the lipid digestive enzyme inhibitor.
Millet, original millet, is widely planted in China, india and other areas, and is a main agricultural product for global consumption and industrial use. Millet contains abundant proteins (7% -12%), and is a good vegetable protein source. The millet protein mainly comprises albumin, globulin, prolamin and alkali-soluble protein, wherein the content of the prolamin is the most, and the prolamin accounts for more than 50% of the total protein. Researches show that the millet prolamin hydrolysate with the activities of resisting oxidation, resisting inflammation, reducing blood pressure, reducing blood sugar and the like can be prepared by taking the millet prolamin as a raw material through enzymolysis. Although frequent consumption of millet has been demonstrated to help alleviate hyperlipidemia, no bioactive peptides for preventing and treating hyperlipidemia are found in the millet prolamin hydrolysate, which has prompted us to further explore the millet prolamin hydrolysate to find novel multi-target, efficient and low-toxic active peptides capable of preventing and treating hyperlipidemia.
Disclosure of Invention
The application firstly uses an enzymolysis method to hydrolyze millet prolamin from different sources, then screens out millet prolamin hydrolysate with the highest enzyme inhibition activity based on the inhibition effect on lipid digestive enzymes (pancrelipase and cholesterol esterase), screens out bioactive peptide through ultrafiltration, peptide sequencing, bioinformatics and other technologies, then utilizes an Fmoc solid-phase synthesis method to prepare bioactive peptide and verifies the inhibition effect on lipid digestive enzymes, and finally clarifies the inhibition mechanism through a molecular docking technology.
In one aspect, the application provides two millet prolamin peptides, the amino acid sequences of which are SEQ ID NO.1 or SEQ ID NO.2.
In another aspect, the application provides the use of the above-described millet prolamin peptides in the preparation of pancreatic lipase and/or cholesterol esterase inhibitors.
In another aspect, the application provides the use of the millet prolamin peptide in preparing a medicament for treating hyperlipidemia.
In another aspect, the application provides application of the millet prolamin peptide in preparation of a weight-losing medicament.
A medicament comprising the above-described millet prolamin peptide.
Further, the medicine also comprises auxiliary materials.
In another aspect, the application provides a method for preparing the millet prolamin peptide, wherein the method is an enzymolysis method or an Fmoc solid-phase synthesis method.
Further, the enzymatic hydrolysis method includes a step of enzymatic hydrolysis of the millet prolamin using pepsin and pancreatin and a step of separation of the above-mentioned millet prolamin peptides.
Further, the Fmoc solid phase synthesis method includes (1) soaking N, N-dimethylformamide and methanol with a molecular sieve to remove impurities; (2) swelling N, N-dimethylformamide activates Wang resin; (3) a first amino acid; (4) Fmoc protecting group removal; (5) attaching a second amino acid and removing the Fmoc protecting group; (6) Repeating the step (5) for a plurality of times until the last amino acid is synthesized and Fmoc protecting groups are removed; (7) The resin is removed and detected by liquid phase and/or mass spectrometry.
The skilled artisan can select suitable methods for isolating the desired peptide from the substrate, including but not limited to chromatography, precipitation, etc., depending on purity and the like.
Methods for Fmoc solid phase synthesis are well known in the art and one skilled in the art can select different reagents and parameters depending on the requirements of the instrument, resin, safety, etc.
The above auxiliary materials can be designed and selected by those skilled in the art according to the stability, solubility and other characteristics of the oligopeptide in combination with general knowledge and instructions in pharmacy.
The liquid phase and mass spectrometry detection methods of the present application can be performed using instruments and consumables commercially available in the art, and suitable parameters and reagents can be determined by those skilled in the art based on general knowledge and appropriate preliminary experiments in the art.
The two millet source hydrophilic/alkaline prolamin peptides, tryptophan-glutamine-histidine-glutamine-tyrosine (Trp-Gln-His-Gln-Tyr, WQHQY), tryptophan-glutamine-histidine-methionine-proline (Trp-Gln-His-Met-Met-Pro, WQHMMP) are obtained by screening by a large amount of work, and have the characteristics of naturalness, no toxicity, no carcinogenicity, small molecular weight and no digestion by gastrointestinal tracts, and the pancreatic lipase and cholesterol esterase inhibition activity is high, the preparation method is simple, the industrial production is easy, and the large-scale preparation can be realized. And further found that they exert enzyme inhibitory activity by hydrophobic interactions, salt bridges, hydrogen bonds, pi-pi stacking, pi-cation interactions in combination with amino acid residues of lipid digestive enzymes. In a word, two kinds of millet prolamin peptides are taken as deep processing products of millet, are novel lipid digestive enzyme inhibitors, can be further developed and utilized as high-quality raw materials in the fields of medicine and the like, are beneficial to preventing, relieving and treating hyperlipidemia, and have higher economic value and good market prospect.
Drawings
FIG. 1 shows the inhibition of lipid digestive enzyme activity of three protein hydrolysates;
FIG. 2 is a high performance liquid chromatography result diagram for bioactive peptides WQHQY (A) and WQHMMP (B);
FIG. 3 is a graph of mass spectra results for bioactive peptides WQHQY (A) and WQHMMP (B);
FIG. 4 shows the inhibition of lipid digestive enzyme activity of two bioactive peptides;
FIG. 5 shows the mechanism of pancreatic lipase activity inhibition for bioactive peptides WQHQY (A) and WQHMMP (B);
FIG. 6 shows the mechanism of inhibition of cholesterol esterase activity by bioactive peptides WQHQY (A) and WQHMMP (B).
Detailed Description
Example 1 extraction of different sources of millet prolamin
The millet No.2, zhaonong No. 21 and red seedling crushing car millet powder are respectively dispersed in n-hexane according to the proportion of 1:5 (w/v), and are oscillated in a water bath at 37 ℃ for 4 hours and are stood for 1 hour. After significant delamination, the upper n-hexane was decanted, the lower precipitate was collected and dried in a fume hood for 12h to completely remove the n-hexane residue. And (5) sieving the air-dried millet degreasing powder with a 60-mesh sieve for standby.
The Zhonggu No.2, zhaonong No. 21 and red seedling crushing and degreasing millet powder are respectively dispersed in 70% ethanol according to the proportion of 1:7 (w/v), are oscillated for 4 hours in a water bath at 37 ℃, are centrifuged for 15 minutes at 8000rpm, and the supernatant is collected. The supernatant was dialyzed with a dialysis bag for 36h, during which distilled water was changed 4-5 times. After the dialysis is finished, the dialyzate is centrifuged at 7000rpm for 5min, and the precipitate is collected and freeze-dried to obtain the millet prolamin.
Example 2 enzymatic hydrolysis of millet prolamin from different sources
The millet No.2, zhaonong No. 21 and red seedling crushing car millet prolamin are respectively and uniformly mixed in distilled water according to the proportion of 5% (w/v), and the pH value of the protein solution is regulated to 2.0 by using 1mol/L HCl. Then adding 4% pepsin (w/w, 250U/mg), mixing, placing into a shaking table, shaking for enzymolysis, wherein the rotation speed of the shaking table is 300rpm, the enzymolysis time is2 hours, and the enzymolysis temperature is 37 ℃. After the pepsin enzymolysis is finished, 0.9mol/L NaHCO is firstly used 3 The pH of the solution was adjusted to 5.3, maintained at pH 7.5 with 1mol/L NaOH, and finally 4% pancreatin (w/w, 8 XSP) was added and digested at 37℃for 2h. And after the pancreatin enzymolysis is finished, the enzymolysis liquid is boiled for 10min, and the residual enzyme is inactivated. Cooling the enzymolysis liquid at room temperature, centrifuging at 4deg.C and 7000 Xg for 20min, and collecting supernatant to obtain millet prolamin hydrolysate.
Example 3 screening of millet prolamin hydrolysates
Based on the inhibition of lipid digestive enzymes (pancreatic lipase and cholesterol esterase), the millet prolamin hydrolysate with the highest enzyme inhibition activity was selected.
(1) Pancreatic lipase Activity inhibition assay
A2.5 mg/mL pancrelipase solution was prepared using phosphate buffer pH 7.3, and the supernatant was then centrifuged at 5500rpm for 5 min. P-nitrophenyl butyrate was diluted to 10mM using phosphate buffer pH 7.3.
After incubating 50. Mu.L of 5mg/mL of medium grain No. 2/Zhaonong No. 21/red seedling frastout millet prolamin hydrolysate solution (equivalent distilled water as control), 40. Mu.L of pancreatic lipase solution and 20. Mu.L of p-nitrobutyrate solution at 37℃for 30min, absorbance was recorded at 405nm by an ELISA reader. The pancreatic lipase activity inhibition rate was calculated as follows:
in the formula (1): a: control absorbance; b: control blank absorbance; c: absorbance of the sample; d: sample blank absorbance. (2) Cholesterol esterase activity inhibition assay
A solution of cholesterol esterase (25. Mu.g/mL) and a solution of p-nitrophenyl butyrate (10 mM) were prepared using phosphate buffer (pH 7.0) containing sodium taurocholate 100mM NaCl,5.16mM, respectively.
After incubating 50. Mu.L of 8mg/mL of medium grain No. 2/Zhaonong No. 21/red seedling frastout millet prolamin hydrolysate solution (equivalent distilled water as a control group), 50. Mu.L of cholesterol esterase solution and 50. Mu.L of p-nitrobutyrate solution at 25℃for 5min, absorbance was recorded at 405nm by an enzyme-labeled instrument. The cholesterol esterase activity inhibition rate was calculated as follows:
in the formula (2): a: control absorbance; b: control blank absorbance; c: absorbance of the sample; d: sample blank absorbance.
The in vitro test results showed that the pancrelipase activity inhibition rates of the prolamin hydrolysates of millet No.2, zhaonong No. 21 and red seedling fraxinus mandshurica were 31.68%, 36.30% and 41.15%, respectively, and the cholesterol esterase activity inhibition rates were 21.97%, 26.87% and 33.66%, respectively (fig. 1). This indicates that three different sources of millet prolamin hydrolysates have the inhibition effect on lipid digestive enzymes, with red seedling crushing car millet prolamin hydrolysates having the best inhibition effect. Based on the above, the inventors selected bioactive peptides meeting development requirements from red seedling crushing car millet prolamin protein hydrolysate serving as a research object.
Ultrafiltration of millet prolamin hydrolysates
Transferring 12mL of millet prolamin hydrolysate solution to a 3kDa centrifugal ultrafiltration tube, centrifuging at 4deg.C and 5000 Xg for 30min to obtain fraction with molecular weight less than 3kDa, freeze-drying and preserving at-20deg.C.
Example 4 peptide sequence identification of <3kDa fraction
After desalting the 3kDa cut sample with a C18 desalting column, the sample was analyzed by LC-MS/MS equipped with an analytical column Acclaim PepMap C18,75 μm X25 cm and an online nano-spray ion source. Sample injection amount: 3 μl, column flow: 300nL/min, column temperature: electrospray voltage at 40 ℃): 2kV. Mobile phase a phase: 0.1% formic acid aqueous solution, phase B: an 80% ACN solution containing 0.1% formic acid. The gradient starts from 4% phase B, equilibrates for 1min, rises to 50% with a nonlinear gradient for 53min 40sec, rises to 95% in 40s, and remains for 5min 40sec.
The mass spectrometer operates in a data dependent acquisition mode, automatically switching between MS and MS/MS acquisition. Mass spectrometry parameters: (1) MS: scan range (m/z): 350-1550, agc target:8e 5 Resolution: 120000, maximum injection time: 100ms; (2) HCD-MS/MS: resolution ratio: 30000, agc target:1e 5 Dynamic exclusion time: 30s, maximum injection time: 54ms. The tandem mass spectrum was analyzed by PEAKS Studio version 10.6.10.6. PEAKS DB searches the uniprot-Seria_itica (version 202204, 35705 entries) database for a peptide fragment with a card value of: -10lgP is more than or equal to 20; the peptide fragment not retrieved in the database was obtained by setting ALC (%) to 80 or more, and a part of typical results are shown in Table 1.
EXAMPLE 5 screening of bioactive peptides
Bioactive peptides as functional ingredients for drugs associated with hyperlipidemia, which are nontoxic, non-carcinogenic and highly potent bioactive are fundamental prerequisites for screening. One of the important considerations for a bioactive peptide to play a healthy role is to ensure that the bioactivity of the peptide is not affected by the digestive system, whereas an active peptide consisting of 2-6 amino acids with a molecular weight below 1000Da may not be digested by the gastrointestinal tract. Therefore, based on bioinformatics technology, the peptide segment in the <3kDa fraction is screened out according to the standards of small molecular weight (< 1000 Da), no toxicity, no carcinogenicity, high potential bioactivity and gastrointestinal indigestion, and the bioactive peptide meeting the development requirements is screened out.
The toxicity of the peptides was predicted using a ToxinPrep (https:// webs. Iitid. Edu. In/raghava/toxinpred/index. Html) platform based on the SVM (Swiss-Port) algorithm. Oncogenic prediction of peptides was performed using admetSAR (http:// lmmd. Ecust. Edu. Cn/admetSAR1/home /). The potential biological activity of the peptides was analyzed by PeptideRanker on-line platform (http:// discoldeep. Ucd. Ie/PeptideRanker /), where thresholds above 0.5 were considered to be biologically active. Gastrointestinal digestibility predictions were performed on peptides based on pepsin and trypsin using PeptideCutter (https:// web. Expasy. Org/peptide_cutter /). The unreported bioactive peptides WQHQY and WQHMMP were first screened from millet prolamin hydrolysates based on low molecular weight (< 1000 Da), non-toxic, non-carcinogenic, high bioactivity (> 0.5) and gastrointestinal indigestion as criteria (see table 1).
The physical properties of the peptides WQHQY and WQHMMP were further predicted using computer software, where the total average hydrophilicity was assessed by ExPasy (https:// web. ExPasy. Org/protparam /), and the isoelectric point by Pepdraw (http:// www.tulane.edu/-biochem/WW/PepDaw /). As shown in Table 1, the overall average hydrophilicity can be used to characterize the hydrophilicity and hydrophobicity of the proteins, where a greater negative value indicates a stronger hydrophilicity, and the results indicate that the peptides WQHQY and WQHMMP have better hydrophilicity. The isoelectric points of the peptides WQHQY and WQHMMP were greater than 7, indicating that they are both basic.
Table 1 bioinformatics-based prediction of prolamin peptide properties of millet
EXAMPLE 6 Synthesis of bioactive peptides
The bioactive peptides WQHQY and WQHMMP are prepared by Fmoc solid-phase synthesis method, and the specific steps are as follows:
(1) Solvent treatment
N, N-Dimethylformamide (DMF), methanol was soaked overnight with G3 pore molecular sieves to remove impurities and water before use.
(2) Fully swelling the resin
2.0g of blank Wang resin was weighed into a clean dry reaction tube, 15mL DMF was added and the mixture was activated at room temperature for 30min.
(3) With the first amino acid
At room temperature, the solvent of the previous step was filtered off with suction through a sand core, 1mmol of the first amino acid at the C-terminus was added in 5-fold molar excess, DMAP was added in 5-fold molar excess, N-diisopropylcarbodiimide was added in 5-fold molar excess, and DMF was taken as solvent for reaction at room temperature for 3 hours. After the reaction is finished, the DMF is used for washing 4 to 6 times, and 5 to 6mL of DMF is used for each time. And adding pyridine and acetic anhydride in a volume ratio of 1:1, and reacting for 30min. After the reaction is finished, the DMF is used for washing 4 to 6 times, and 5 to 6mL of DMF is used for each time.
(4) Leaving of Fmoc protecting group
Removing the solvent of (3) by suction filtration, adding 10mL of 20% piperidine DMF solution to the resin, N 2 After stirring for 10min, the solution was filtered off and 10mL of 20% piperidine DMF solution, N was added 2 After repeated twice the solution was filtered off with stirring for 5min, washed with DMF 4 times and methanol 2 times, 5-6mL each time.
(5) Ninhydrin detection removal effect
Taking out a small amount of resin, washing with methanol for three times, adding ninhydrin, KCN and phenol solution into the resin, heating the mixture at 105-110 ℃ for 5min to turn deep blue into positive reaction, and performing the next reaction after the complete removal; if colorless, indicating that the protecting group is not removed completely, the above deprotection operation needs to be repeated.
(6) Grafting a second amino acid and removing Fmoc protecting group
Weighing 3 times molar excess of the second amino acid at the C end, 3 times molar excess of HBTU and 3 times molar excess of 1-hydroxybenzotriazole in a reaction tube, adding a proper amount of DMF solution to dissolve the second amino acid completely, adding 10 times molar excess of N, N-diisopropylethylamine, reacting for 40min at room temperature, washing 4-6 times with DMF, and 5-6mL each time. Taking a small amount of resin, detecting with ninhydrin detection reagent to display colorless, then adding 10mL of 20% piperidine DMF solution to remove Fmoc, and performing twice for 10min and 5min respectively, and then washing with DMF for 4 times and methanol for 2 times, wherein each time is 5-6mL. Taking out a small amount of resin, detecting with ninhydrin detection reagent, and detecting to be blue, thus the next reaction can be carried out.
(7) And repeating the step (6) until the last amino acid at the N end is synthesized, removing the Fmoc protecting group, and then pumping.
(8) Separation and detection of resin and pure product
Finally, trifluoroacetic acid cutting fluid (95% trifluoroacetic acid: 2% triisopropylsilane: 2% ethanedithiol: 1%H) is used 2 O) cutting for 2h, filtering the reaction solution to obtain trifluoroacetic acid solution of peptide, blow-drying the lysate with nitrogen, precipitating with diethyl ether, centrifuging, washing with diethyl ether for 3-5 times to obtain white solid, dissolving with pure water, desalting and purifying by HPLC, and freeze-drying to precipitate crystals.
(9) Peptide mass detection
And taking a small amount of sample, dissolving the sample by ultrasonic, and then placing the sample in an analytical high performance liquid chromatograph for detection. The HPLC parameters were: chromatographic column: 4.6X 250mm,Sinochrom ODS-BP 5 μm; mobile phase a:100% acetonitrile plus 0.1% trifluoroacetic acid; mobile phase B:100% water plus 0.1% trifluoroacetic acid; flow rate: 1mL/min; sample injection amount: 5 μl, detection wavelength: 220nm.
For WQHQY, the gradient procedure is as follows:
for WQHMMP, the gradient procedure is as follows:
Agilent-6125B Mass Spectrometry parameters: the ion source is an electrospray ionization source (ESI source), atomizing gas flow rate: 1.5L/min, CDL: -20.0v, cdl temperature: heating block temperature of 250 DEG CDegree: 200 ℃, ion source voltage: +4.5kV, detector voltage: 1.5kV, mobile phase flow rate: 0.2mL/min, mobile phase ratio: 50% H 2 O/50％ACN。
Finally, through high performance liquid chromatography and mass spectrometry analysis, the purity of the peptides WQHQY and WQHMMP is determined to be more than 95%, and specific chromatography and mass spectrometry results are shown in figures 2 and 3 respectively.
EXAMPLE 7 evaluation of lipid digestive enzyme inhibition effect of bioactive peptide
(1) Pancreatic lipase Activity inhibition assay
A2.5 mg/mL pancrelipase solution was prepared using phosphate buffer pH 7.3, and the supernatant was then centrifuged at 5500rpm for 5 min. P-nitrophenyl butyrate was diluted to 10mM using phosphate buffer pH 7.3.
After incubation of 50. Mu.L of 5mg/mL WQHQY/WQHMMP solution (equivalent distilled water as control), 40. Mu.L of pancrelipase solution and 20. Mu.L of p-nitrobutyrate solution at 37℃for 30min, absorbance was recorded at 405nm by an microplate reader. The pancreatic lipase activity inhibition rate was calculated as follows:
in the formula (1): a: control absorbance; b: control blank absorbance; c: absorbance of the sample; d: sample blank absorbance. (2) Cholesterol esterase activity inhibition assay
A solution of cholesterol esterase (25. Mu.g/mL) and a solution of p-nitrophenyl butyrate (10 mM) were prepared using phosphate buffer (pH 7.0) containing sodium taurocholate 100mM NaCl,5.16mM, respectively.
After incubating 50. Mu.L of 8mg/mL WQHQY/WQHMMP solution (equivalent distilled water as control), 50. Mu.L of cholesterol esterase solution and 50. Mu.L of p-nitrobenzoate solution at 25℃for 5min, absorbance was recorded at 405nm by an enzyme-labeled instrument. The cholesterol esterase activity inhibition rate was calculated as follows:
in the formula (2): a: control absorbance; b: control blank absorbance; c: absorbance of the sample; d: sample blank absorbance.
The in vitro test results showed that the pancrelipase activity inhibition rates of the bioactive peptides WQHQY and WQHMMP were 66.77% and 61.58%, respectively, and the cholesterol esterase activity inhibition rates were 45.75% and 38.33%, respectively (fig. 4). This indicates that both bioactive peptides have better enzyme inhibition activity on pancreatic lipase and cholesterol esterase. In a word, the two millet prolamin peptides can effectively prevent, relieve and treat hyperlipidemia, are expected to be widely applied to medicines related to the hyperlipidemia as functional components, and have good market prospect.
EXAMPLE 8 analysis of lipid digestive enzyme inhibition mechanism of bioactive peptide
The screened bioactive peptide is used as ligand, lipid digestive enzyme (pancreatic lipase and cholesterol esterase) is used as receptor, and the action site and interaction force between bioactive peptide and lipid digestive enzyme are defined by molecular docking technology, so as to further clarify the inhibition mechanism.
(1) Peptide WQHQY and WQHMMP for pancreatic lipase molecular docking assays
The crystal structure of pancreatic lipase (PDB number: 1 ETH) was obtained from the RCSB protein database (http:// www.rcsb.org /), peptides WQHQY and WQHMMP were semi-flexibly docked with pancreatic lipase using Dock 6.9, and energy evaluation was performed based on Grid scoring function. Chain a (containing 448 amino acid residues) of pancreatic lipase molecules was retained for docking analysis prior to molecular docking, while co-crystallizing molecules and other polypeptide chains were removed. The molecular docking is centered on the pancreatic lipase active sites (Ser 153, asp177 and His 264), i.e. the coordinates are X:64.152, Y:39.278, z:127.241. docking scoring is an approximate potential for ligand binding to a macromolecule, with lower scoring values indicating strong affinity between the macromolecule of interest and the ligand. Van der Waals force contributions refer to nonpolar effects such as pi-pi stacking, hydrophobic interactions, and the like. Electrostatic force contribution is represented by polar actions such as salt bridge, hydrogen bond and the like. The butt score is the sum of the van der Waals force contribution and the electrostatic force contribution. Table 2 shows that the peptide WQHQY has a docking score of-90.1657 kcal/mol, a Van der Waals force contribution of-88.583 kcal/mol, an electrostatic force contribution of-1.5827 kcal/mol, and an internal repulsive energy of 21.5718kcal/mol; the docking score of peptide WQHMMP with pancreatic lipase was-99.0293 kcal/mol, van der Waals force contribution was-98.6513 kcal/mol, electrostatic force contribution was-0.378 kcal/mol, and internal repulsion energy was 25.9525kcal/mol. A docking score value of typically less than-50 kcal/mol indicates a better binding force. The larger the internal repulsive energy value, the larger the repulsive force, indicating that the conformation is unstable, whereas an internal repulsive energy of less than 30kcal/mol indicates that the conformation is stable. The docking scores of both bioactive peptides with pancreatic lipase were below-50 kcal/mol and the internal rejection energy was also below 30kcal/mol, indicating that both could form a stable binding state with pancreatic lipase.
Molecular docking simulation figure 5A demonstrates that binding of peptide WQHQY to pancrelipase amino acid residues relies primarily on hydrophobic interactions, pi-pi stacking, and hydrogen bonding. Specifically, peptide WQHQY forms a hydrophobic interaction with amino acid residues (Phe 216, phe78, leu265, ile79, val260, trp 253), forms pi-pi stacking with amino acid residue (His 264), and forms a hydrogen bond with amino acid residues (Ser 153, asp80, thr 113).
Molecular docking simulation figure 5B demonstrates that binding of peptide WQHMMP to pancrelipase amino acid residues relies primarily on hydrophobic interactions, salt bridges, and hydrogen bonds. Specifically, peptide WQHMMP forms a hydrophobic interaction with amino acid residue (Phe 216, asn 263), forms a salt bridge with amino acid residue (Arg 257, his 152), and forms a hydrogen bond with amino acid residue (Leu 214).
The pancreatic lipase N-terminal domain contains the active site of the acyl enzyme catalytic triplets Ser153, asp177, his264 and the substrate binding residues Phe78, his152, phe 216. The peptide WQHQY occupies catalytic sites through pi-pi stacking and hydrogen bonding, and occupies substrate binding sites through hydrophobic interactions to inhibit pancreatic lipase activity; the peptide WQHMMP inhibits pancreatic lipase activity by occupying the substrate binding site through hydrophobic interactions and hydrogen bonds.
(2) Cholesterol esterase molecular docking assay with peptides WQHQY and WQHMMP
The crystal structure of cholesterol esterase (PDB number: 1F 6W) was obtained from the RCSB protein database (http:// www.rcsb.org /), peptides WQHQY and WQHMMP were semi-flexibly docked with cholesterol esterase using Dock 6.9, and energy evaluation was performed based on a Grid scoring function. Excess water molecules were removed prior to molecular docking, while molecular docking was centered on the cholesterol esterase active sites (Ser 194, asp320 and His 435), i.e. coordinates X:8.039, Y: -1.404, z:21.544. table 2 shows that the peptide WQHQY has a docking score with cholesterol esterase of-104.3077 kcal/mol, a Van der Waals force contribution of-101.3097 kcal/mol, an electrostatic force contribution of-2.9981 kcal/mol, and an internal repulsive energy of 19.4904kcal/mol; the docking score for peptide WQHMMP cholesterol esterase was-107.7835 kcal/mol, the Van der Waals force contribution was-103.2768 kcal/mol, the electrostatic force contribution was-4.5067 kcal/mol, and the internal repulsive energy was 28.2383kcal/mol. The docking scores of both bioactive peptides with cholesterol esterase were below-50 kcal/mol, and the internal rejection energy was also below 30kcal/mol, indicating that both could form a stable binding state with cholesterol esterase.
Molecular docking simulation figure 6A demonstrates that binding of peptide WQHQY to cholesterol esterase amino acid residues is primarily dependent on hydrophobic interactions, pi-cationic interactions, and hydrogen bonding. Specifically, peptide WQHQY forms a hydrophobic interaction with amino acid residues (Ile 439, ala436, ala108, val285, met281, leu392, phe 324), a pi-cationic interaction with amino acid residue (Lys 445), and a hydrogen bond with amino acid residues (Tyr 453, gly 107).
Molecular docking simulation figure 6B demonstrates that binding of peptide WQHMMP to cholesterol esterase amino acid residues is primarily dependent on salt bridging, hydrophobic interactions, and hydrogen bonding. Specifically, peptide WQHMMP forms a salt bridge with amino acid residues (Lys 445), forms a hydrophobic interaction with amino acid residues (Ile 439, phe119, ala108, val285, phe324, met 281), and forms a hydrogen bond with amino acid residues (Tyr 453, ser 194).
Cholesterol esterases have an N-terminal catalytic domain comprising catalytic triplets Ser194, asp320 and His435. The substrate binding site is formed by Gly107, ala108 and Ala195 adjacent Ser 194. The peptide WQHQY occupies the substrate binding site through hydrophobic interactions and hydrogen bonds; the peptide WQHMMP occupies catalytic sites through hydrogen bonds and occupies substrate binding sites through hydrophobic interactions to inhibit cholesterol esterase activity.
TABLE 2 molecular docking results for two bioactive peptides

Claims (4)

1. The millet prolamin peptide is characterized in that the amino acid sequence of the millet prolamin peptide is SEQ ID NO.1.
2. Use of a millet prolamin peptide according to claim 1 for the preparation of pancreatic lipase and/or cholesterol esterase inhibitors.
3. A method for preparing a millet prolamin peptide of claim 1, wherein said method is an Fmoc solid phase synthesis method.
4. The method of claim 3, wherein the Fmoc solid phase synthesis method comprises (1) soaking N, N-dimethylformamide and methanol with molecular sieves to remove impurities; (2) swelling N, N-dimethylformamide activates Wang resin; (3) a first amino acid; (4) Fmoc protecting group removal; (5) attaching a second amino acid and removing the Fmoc protecting group; (6) Repeating the step (5) for a plurality of times until the last amino acid is synthesized and Fmoc protecting groups are removed; (7) The resin is removed and detected by liquid phase and/or mass spectrometry.
CN202211672882.7A 2022-12-26 2022-12-26 Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities Active CN115925854B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211672882.7A CN115925854B (en) 2022-12-26 2022-12-26 Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities
CN202311088956.7A CN117003845B (en) 2022-12-26 2022-12-26 Millet prolamin peptide and its use in treating hyperlipoidemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211672882.7A CN115925854B (en) 2022-12-26 2022-12-26 Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311088956.7A Division CN117003845B (en) 2022-12-26 2022-12-26 Millet prolamin peptide and its use in treating hyperlipoidemia

Publications (2)

Publication Number Publication Date
CN115925854A CN115925854A (en) 2023-04-07
CN115925854B true CN115925854B (en) 2023-08-25

Family

ID=86553953

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311088956.7A Active CN117003845B (en) 2022-12-26 2022-12-26 Millet prolamin peptide and its use in treating hyperlipoidemia
CN202211672882.7A Active CN115925854B (en) 2022-12-26 2022-12-26 Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202311088956.7A Active CN117003845B (en) 2022-12-26 2022-12-26 Millet prolamin peptide and its use in treating hyperlipoidemia

Country Status (1)

Country Link
CN (2) CN117003845B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003845B (en) * 2022-12-26 2024-03-29 中国农业大学 Millet prolamin peptide and its use in treating hyperlipoidemia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027268D0 (en) * 1989-12-25 1991-02-06 Nisshin Flour Milling Co Lipolytic enzyme inhibitors
JPH03284627A (en) * 1989-12-25 1991-12-16 Nisshin Flour Milling Co Ltd Lipid hydrolyzing enzymen inhibitor
JPH05339168A (en) * 1992-06-08 1993-12-21 Suisanchiyou Chokan Pancreatic lipase inhibitor and cholesterol esterase inhibitor
WO2013085337A1 (en) * 2011-12-09 2013-06-13 포항공과대학교 산학협력단 Composition for treatment or prevention of obesity, containing water extracts of perenniporia fraxinea
CN114634552A (en) * 2022-04-14 2022-06-17 中国农业大学 Anti-obesity tridecapeptide and application thereof
CN114773430A (en) * 2022-04-14 2022-07-22 中国农业大学 Three cholesterol-lowering peptides with cholesterol esterase inhibitory activity and application thereof
CN114805483A (en) * 2022-04-02 2022-07-29 中国农业大学 Five pancreatic lipase inhibitors derived from small red bean protein and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187295A2 (en) * 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN115806589B (en) * 2022-12-09 2023-05-23 中国农业大学 Two millet-derived oligopeptides and application thereof in treatment of metabolic syndrome
CN117003845B (en) * 2022-12-26 2024-03-29 中国农业大学 Millet prolamin peptide and its use in treating hyperlipoidemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027268D0 (en) * 1989-12-25 1991-02-06 Nisshin Flour Milling Co Lipolytic enzyme inhibitors
JPH03284627A (en) * 1989-12-25 1991-12-16 Nisshin Flour Milling Co Ltd Lipid hydrolyzing enzymen inhibitor
JPH05339168A (en) * 1992-06-08 1993-12-21 Suisanchiyou Chokan Pancreatic lipase inhibitor and cholesterol esterase inhibitor
WO2013085337A1 (en) * 2011-12-09 2013-06-13 포항공과대학교 산학협력단 Composition for treatment or prevention of obesity, containing water extracts of perenniporia fraxinea
CN114805483A (en) * 2022-04-02 2022-07-29 中国农业大学 Five pancreatic lipase inhibitors derived from small red bean protein and application thereof
CN114634552A (en) * 2022-04-14 2022-06-17 中国农业大学 Anti-obesity tridecapeptide and application thereof
CN114773430A (en) * 2022-04-14 2022-07-22 中国农业大学 Three cholesterol-lowering peptides with cholesterol esterase inhibitory activity and application thereof

Also Published As

Publication number Publication date
CN117003845A (en) 2023-11-07
CN117003845B (en) 2024-03-29
CN115925854A (en) 2023-04-07

Similar Documents

Publication Publication Date Title
Zambrowicz et al. Multifunctional peptides derived from an egg yolk protein hydrolysate: isolation and characterization
CN114805483B (en) Five pancreatic lipase inhibitors derived from small red bean protein and application thereof
CN115925854B (en) Two millet prolamin peptides for inhibiting pancreatic lipase and cholesterol esterase activities
CN114773430B (en) Three cholesterol-lowering peptides with cholesterol esterase inhibitory activity and application thereof
Cian et al. Identification and in silico study of a novel dipeptidyl peptidase IV inhibitory peptide derived from green seaweed Ulva spp. hydrolysates
CN117247431B (en) Tartary buckwheat peptide with DPP-IV inhibitory activity and application thereof
CN114716523B (en) Millet prolamin peptides with alpha-glucosidase inhibitory activity
CN117820431B (en) Highland barley distillers&#39; grain peptide with uric acid reducing effect, and preparation method and application thereof
Chen et al. Novel ACE inhibitory peptides derived from bighead carp (Aristichthys nobilis) hydrolysates: Screening, inhibition mechanisms and the bioconjugation effect with graphene oxide
CN114634552A (en) Anti-obesity tridecapeptide and application thereof
Xiang et al. Two novel angiotensin I-converting enzyme inhibitory peptides from garlic protein: In silico screening, stability, antihypertensive effects in vivo and underlying mechanisms
CN116479077A (en) Preparation method of high-activity tartary buckwheat albumin antihypertensive peptide
CN115806589B (en) Two millet-derived oligopeptides and application thereof in treatment of metabolic syndrome
CN114891065A (en) Blood sugar-reducing sea cucumber peptide with alpha-amylase inhibitory activity and preparation method and application thereof
CN115838400B (en) Two small red bean peptides for targeting prevention or treatment of metabolic syndrome
Liu et al. Isolation and characterization of oligopeptides with vascular disease suppression effects derived from wheat gluten
EA012972B1 (en) Tripeptide map and tripeptide itp or salts thereof, protein hydrolysates and mixtures containing said tripeptides or salts thereof for blood pressure lowering
Du et al. Preparation, identification, and inhibitory mechanism of dipeptidyl peptidase IV inhibitory peptides from goat milk whey protein
JP2673659B2 (en) peptide
CN117106020B (en) Small red bean-derived oligopeptide with digestive enzyme inhibition activity and application thereof
JPS61171431A (en) Amylase-inhibiting substance and preparation thereof
CN118436757A (en) Medicine for treating hyperuricemia and gout and preparation method thereof
CN115677826B (en) Walnut acetylcholinesterase inhibiting peptide and application thereof
CN118373879A (en) Highland barley oligopeptide for treating metabolic syndrome
CN116041428B (en) Two ACE (angiotensin converting enzyme) inhibitory peptides as well as preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant